基于2型糖尿病并发心血管疾病的影响因素分析

祥任 谷(湖南省张家界市永定区第一人民医院，中国)

摘要

本研究探讨了心血管疾病和 2 型糖尿病患者之间影响因素的分析，并探讨了卡那列净对于患有心血管疾病的 2 型糖尿病患者的治疗效果。通过对四个 3 期研究的数据进行汇总分析，评估 HbA1c，体重和收缩压等指标的变化。根据不良事件的发生情况报告评估安全性。结果发现卡那列净可降低患有心血管疾病的 2 型糖尿病患的 HbA1c，体重和收缩压，且不会导致不良事件发生的概率。得出结论，卡那列净的疗效和安全性在 2 型糖尿病合并不同程度的心血管疾病的患者中效果基本一致，在 2型糖尿病患者中普遍耐受良好。由于 CV 疾病对于 2 型糖尿病患者是很重的负担，为 2 型糖尿病和 CV 疾病的患者寻求安全有效的治疗策略具有极大的临床需求，本文的研究结果对于 2 型糖尿病和 CV 疾病患者的治疗提供了一定的指导意义。　

关键词

2 型糖尿病；心血管疾病；卡那列净

参考

International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation,2015.

Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative metaanalysis of 102 prospective studies. Lancet,2010(9733):2215-22.

Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes,1999(05):937.

Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes

mellitus—mechanisms, management, and clinical considerations. Circulation,2016(24):2459.

Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes Vasc Dis Res,2015(02):90-100.

Johansen OE. Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis. Scand J Clin Lab Investig,2007(08):786-800.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: apatientcentered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care,2015.

Wami WM, Buntinx F, Bartholomeeusen S, Goderis G, Mathieu C, Aerts M. Influence of chronic comorbidity and medication on the efficacy of treatment in patients with diabetes in general practice. Br J Gen Pract,2013.

GLUCOTROL (glipizide) TABLETS [package insert]. New York: Roerig,2008.

Glynase PresTab (micronized glyburide tablets) [package insert]. New York: Pharmacia & Upjohn Company,2010.

ACTOS (pioglitazone) tablets for oral use [package insert]. Deerfield: Takeda Pharmaceuticals America, Inc,2013.

Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab,2011.

Polidori D, Sha S, Ghosh A, Plum-Morschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab,2013.

Rosenthal N, Meininger G, Ways K, Polidori D, Desai M, Qiu R, Alba M, Vercruysse F, Balis D, Shaw W, et al. Canagliflozin: a sodium glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci,2015.

Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C,Canovatchel W, Meininger G. Efficacy and safety of canagliflozin 102Mathieu C, Vercruysse F, Usiskin K, Law G, Black S, Canovatchel W, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract,2013.

Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab,2014(05):467. monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab,2013.

Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia,2013.

Wilding JP, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruysse F, Usiskin K, Law G, Black S, Canovatchel W, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract,2013.

DOI: http://dx.doi.org/10.26549/yzlcyxzz.v3i2.3820